Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chinese Pharmaceutical Industry Enjoys Capital Influx

This article was originally published in PharmAsia News

Executive Summary

Investment in China's medical sector in 2007 far exceeded previous years, and the number of venture capitalists eager to pump in funds is increasing. A funding consultant in Shanghai disclosed that as of last August, 12 medical-related enterprises had received nearly $200 million in investments - probably representing only the tip of the iceberg - compared with barely $100 million in 2006. More than half the funds went into the medical device domain, the hot favorite due to its short R&D cycle and growing demand propelled by an aging population. Health care services and medical outsourcing such as contract research are emerging as attractive bets. The quality improvement of local R&D capability and operations also contributed to the surge in investment. (Click here for more)

You may also be interested in...

QUOTED. 22 October. Robert Ford.

Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.

China Regulatory Express: Biosecurity Law, Export Controls And The Life Science Sector

With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.

Mediocre Vaccine Could Make Pandemic Worse, Non-Profit Group Tells US FDA

Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts